In view of the above ACE2 effects and drug characteristics, we can rationally use ACE2 inhibitors for cancer patients with high expression of ACE2, while for patients with low expression of ACE2 or poor prognosis and unknown mechanisms such as KICH, TGCT, and THCA, ACE2 inhibitors should be used with caution. The gene discussed is ACE2; the disease is cancer.